Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (3915)	3/10/1998 7:31:00 AM
From: biodoc	Read Replies (1) \| Respond to of 6136

Go to www.agouron.com for a description of the Rhinovirus 3C protease inhibitor program. Rhinoviruses cause the common cold, and the 3C protease inhibitors should work on all strains. They have had a number (reading between the lines, I don't KNOW this) of candidates in preclinical development and are about to select one for further development. I am sure it will get lots of press and drive the stock up, but it is a long way from being shown to be effective, and a long way from a viable product. How would it be used? What would it cost? By the time you know you have the common cold, is there any point in treating the virus? etc. etc. etc. Maybe if it could be administered by nasal spray after known exposures, it would prevent the common cold. That might be a good market.